--- canonical_url: https://www.stockexpertai.com/earnings/iqv last_updated: 2026-05-09T11:54:53.153Z --- # IQVIA Holdings Inc. (IQV) Q4 FY2026 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-09T11:54:52.705Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $178.71 (▲ 0.04%) | fmp:quote | | Market Cap | $29.8B | fmp:profile | | 52w range | $134.65 – $247.05 | fmp:quote | | Earnings | Tue 28 Jul | fmp:earnings-history | | EPS estimate | $3.03 (+8% YoY) | fmp:earnings-estimate | | Revenue estimate | $4.3B | fmp:earnings-estimate | | Beat streak | 8/4 | fmp:earnings-history | | Rating | A- (overall 4/5) | fmp:ratings | | Analyst median target | $223 (+24.5% upside) | fmp:price-target-consensus | | MoonshotScore | 40/100 | derived | | Council | 3/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## IQVIA Holdings Inc. — Q4 FY2026 Expectations Q4 consensus: revenue $4.3B^{[FMP est]}, EPS $3.03^{[FMP est]}. 8 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** A- · **Stance:** BUY · **Council:** 3/6 · **Moonshot:** 40 = MoonshotScore 40^{[9-pillar formula]} + Council 3/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (5 metrics) ### 1. Fy26 Eps Guidance Increase IQVIA Holdings Inc. reaffirmed its full year 2026 guidance for revenue and adjusted EBITDA and raised the guidance for adjusted diluted earnings per share. > "We repurchased $552 million of our shares in the first quarter, and we reaffirmed our full year 2026 guidance for revenue and adjusted EBITDA and raised the guidance for adjusted diluted earnings per share." > — Michael Fedock, Executive Vice President and Chief Financial Officer, Expectation / Guide · Q1 FY2026 ### 2. Ai Agent Deployment IQVIA Holdings Inc. has deployed 192 agents in the field covering 64 use cases across Commercial and R&D Solutions, with 19 of the top 20 pharma companies trusting its AI capabilities. > "To date, we have 192 agents deployed in the field covering 64 use cases across both our Commercial Solutions and R&D Solutions businesses. Nineteen of the top twenty pharma companies are already using IQVIA Holdings Inc. agents in some of their workflows, underscoring broad industry trust in our AI capabilities." > — Ari Bousbib, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 3. Record Backlog IQVIA Holdings Inc.’s backlog reached a new record of $34.2 billion, with $8.9 billion expected to convert to revenue in the next twelve months. > "Our backlog reached a new record of $34.2 billion at the end of the quarter. Noteworthy is the amount of dollars from our backlog that will convert to revenue in the next twelve months. We have $8.9 billion out of our backlog, representing nearly 8% growth year over year versus the recast numbers last year." > — Ari Bousbib, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 4. Commercial Solutions Growth IQVIA Holdings Inc. saw its organic revenue growth rate in Commercial Solutions double. > "In fact, year over year, our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled." > — Ari Bousbib, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 5. Rd Solutions Growth IQVIA Holdings Inc. saw its organic revenue growth rate in R&D Solutions triple. > "In fact, year over year, our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled." > — Ari Bousbib, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 2.0 | weak | Q1 vs Q2: moderate growth (+3.3%) | | Gross Margin | 3.0 | weak | Q1: average margin (32.6%) | | Operating Leverage | 1.0 | weak | op margin average (12.4%) | | Cash Runway | 3.0 | weak | FCF very strong ($0.6B, 618000000.0× CapEx) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 7.0 | strong | RSI 60.4 positive momentum, 50d above | | News Sentiment | 9.0 | strong | strong buy consensus (91%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +24.5% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | neutral | quant · RSI 60 | | Klarman | neutral | value · target upside +24.5% | | Buffett | bull | quality · ROE score 5/5 | | Munger | neutral | valuation · target upside +24.5% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Strong - **Margin of Safety:** Moderate - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 60.4 — yükselişte nötr — overbought sınırının altında, momentum pozitif - **50d MA:** $170 — hisse %5.2 üstünde — kısa vadeli destek - **200d MA:** $197 — hisse %9.3 altında — uzun vadeli baskı - **Volume (10d):** -46% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $2.81 | $2.77 | BEAT | +3.7% | | Q3 FY25 | $3.00 | $2.98 | BEAT | -0.1% | | Q4 FY25 | $3.42 | $3.40 | BEAT | +3.6% | | Q1 FY26 | $2.90 | $2.83 | +2.5% EPS | +0.0% | Q1 (May 5, 2026): EPS $2.90 vs $2.83 est^[FMP], +2.5% beat. D+1 movement: +0.0%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $3.03 + CapEx discipline** Threshold: EPS > $3.03^{[FMP est]}. Target: Break above median target $223^{[FMP target]}; high target $250^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $3.03 + CapEx < $0** Threshold: EPS ≈ $3.03^{[FMP est]}, Q4 CapEx < $0^[FMP]. Target: Consolidation in the band between current $179^[FMP] and median $223^[FMP]. ### Scenario C · Miss **EPS < $2.94 or CapEx ≥ $0** Threshold: EPS < $2.94^{[FMP est×0.97]}. Target: Current $179 below SMA200 $197^[FMP], if rejection continues, $167^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $2.90 vs $2.83 beat^[FMP], stock +0.0% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $0^{[FMP cashflow]}. Q1 op margin 12.4%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $223 (+24.5% upside vs current $179) - **High / Low:** $250 / $185 - **Buy / Hold / Sell:** 21 / 2 / 0 - **Analyst count:** 5 (last quarter), 53 all-time ## Additional Transcript Insights ### 1. commercial_solutions_growth **Claim:** IQVIA Holdings Inc. saw its organic revenue growth rate in Commercial Solutions double. **Evidence (transcript):** "In fact, year over year, our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled." **Numbers:** doubled, tripled ### 2. rd_solutions_growth **Claim:** IQVIA Holdings Inc. saw its organic revenue growth rate in R&D Solutions triple. **Evidence (transcript):** "In fact, year over year, our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled." **Numbers:** doubled, tripled ### 3. ai_impact_on_demand **Claim:** AI is causing clients to have more questions, increasing demand for IQVIA Holdings Inc.’s differentiated AI capabilities and innovation in its commercial offerings. **Evidence (transcript):** "AI is causing our clients to have more questions. It is causing them to increase their demand for IQVIA Holdings Inc.’s differentiated AI capabilities and for the innovation we are embedding across our commercial offerings." **Numbers:** — ### 4. record_backlog **Claim:** IQVIA Holdings Inc.’s backlog reached a new record of $34.2 billion, with $8.9 billion expected to convert to revenue in the next twelve months. **Evidence (transcript):** "Our backlog reached a new record of $34.2 billion at the end of the quarter. Noteworthy is the amount of dollars from our backlog that will convert to revenue in the next twelve months. We have $8.9 billion out of our backlog, representing nearly 8% growth year over year versus the recast numbers last year." **Numbers:** $34.2 billion, $8.9 billion, 8% ### 5. ai_agent_deployment **Claim:** IQVIA Holdings Inc. has deployed 192 agents in the field covering 64 use cases across Commercial and R&D Solutions, with 19 of the top 20 pharma companies trusting its AI capabilities. **Evidence (transcript):** "To date, we have 192 agents deployed in the field covering 64 use cases across both our Commercial Solutions and R&D Solutions businesses. Nineteen of the top twenty pharma companies are already using IQVIA Holdings Inc. agents in some of their workflows, underscoring broad industry trust in our AI capabilities." **Numbers:** 192, 64, 19, twenty ### 6. fy26_eps_guidance_increase **Claim:** IQVIA Holdings Inc. reaffirmed its full year 2026 guidance for revenue and adjusted EBITDA and raised the guidance for adjusted diluted earnings per share. **Evidence (transcript):** "We repurchased $552 million of our shares in the first quarter, and we reaffirmed our full year 2026 guidance for revenue and adjusted EBITDA and raised the guidance for adjusted diluted earnings per share." **Numbers:** $552 million, 2026 --- *Data source: FMP (live query, 2026-05-09), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*